Literature DB >> 7407337

Investigation of the Urinary excretion of pethidine and five of its metabolites in man using selected ion monitoring.

C Lindberg, U Bondesson, P Hartvig.   

Abstract

The urinary excretion in man of pethidine and five of its metabolites (norpethidine, pethidinic acid, norpethidinic acid, p-hydroxypethidine and pethidine N-oxide) after a single intramuscular dose has been investigated using analytical procedures based on selected ion monitoring. New methods for the determination of p-hydroxypethidine and pethidine N-oxide have been developed, and the selectivity and sensitivity of the procedures are discussed. Only some 5% of the administered dose was excreted as unchanged pethidine. The mean urinary excretion of norpethidine was 16.4%. Pethidinic acid and norpethidinic acid constituted the major fraction of the dose excreted in urine. The total excretion of pethidinic acid and norpethidinic acid was 41.7 and 23.2%, respectively. Pethidine N-oxide constituted less than 0.5% of the excreted amount, and p-hydroxypethidine could only be detected in the urine of two of the patients. A mean total recovery of about 90% of the dose was found in urine as pethidine and the five metabolites.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7407337     DOI: 10.1002/bms.1200070210

Source DB:  PubMed          Journal:  Biomed Mass Spectrom        ISSN: 0306-042X


  3 in total

Review 1.  Clinical pharmacokinetics of pethidine: 1982.

Authors:  D J Edwards; C K Svensson; J P Visco; D Lalka
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

2.  Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

3.  Comparison of renal excretion of pethidine (meperidine) and its metabolites in old and young patients.

Authors:  I Odar-Cederlöf; L O Boréus; U Bondesson; L Holmberg; L Heyner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.